Trial Profile
A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Dec 2023
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary) ; Meningococcal vaccine group C conjugate; Pneumococcal 10-valent vaccine conjugate
- Indications Meningococcal group B infections
- Focus Therapeutic Use
- Sponsors Novartis Vaccines
- 18 Jul 2019 Results of a post-hoc analysis assessing PHiD-CV immunogenicity when co-administered with 4CMenB and/or a CRM-conjugated meningococcal serogroup C vaccine, published in the Vaccine
- 15 Mar 2017 Results published in the Vaccine
- 13 May 2016 Results published in a GlaxoSmithKline media release.